BioCentury
ARTICLE | Clinical News

Ampio sags after OA candidate's latest miss

July 1, 2016 1:06 AM UTC

Ampio Pharmaceuticals Inc. (NYSE-M:AMPE) fell $2.03 (61%) to $1.29 on Thursday after Ampion missed the primary endpoint of significantly reducing WOMAC-A pain subscale scores vs. saline control in the Phase III PIVOT trial to treat osteoarthritis pain. Ampion did significantly reduce pain scores from baseline in the 480-patient study.

Despite the miss, Ampio said it plans to seek approval of Ampion in the most severe OA patients, for whom there is no available non-surgical therapy. The company said data from three single injection studies of Ampion showed the therapy led to a significant benefit over saline on three endpoints including WOMAC pain scores in those patients. ...